It’s shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share ...

Coral Gables, FL-based Catalyst Pharmaceuticals , Inc. (NASDAQ:CPRX), a $2.69 billion market cap biopharmaceutical company that has delivered an impressive 54% return to shareholders over the past ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

This was the stock's second consecutive day of losses.

CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 11.63% ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) recently disclosed in an 8-K filing with the Securities and Exchange Commission on January 13, 2025, that the company has posted a corporate presentation ...

Computational simulations revealed that the copper clusters’ specific atomic configuration facilitates the bonding of CO2 ...

AGAMREE® is a trademark of Santhera Pharmaceuticals.

This follows confirmation that no appeals were received against the Final Draft Guidance (FDG) recommendation announced on December 10, 2024. Following this, Santhera has already started launch ...